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Parkinson’s disease (PD) is one of the most prevalent forms of
synucleinopathies, and it is characterized neuropathologically
by the presence of intracellular inclusions composed primarily
of the protein a-synuclein (a-syn) in neurons. The previous
immunotherapy targeting the a-syn in PD models with mono-
clonal antibodies has established a-syn protein as an effective
target for neuronal cell death. However, due to the essential
weaknesses of antibody and the unique features of aptamers,
the aptamers could represent a promising alternative to the
currently used antibodies in immunotherapy for PD. In this
study, the purified human a-syn was used as the target for
in vitro selection of aptamers using systematic evolution by
exponential enrichment. This resulted in the identification of
two 58-base DNA aptamers with a high binding affinity and
good specificity to the a-syn, with KD values in the nanomolar
range. Both aptamers could effectively reduce a-syn aggrega-
tion in vitro and in cells and target the a-syn to intracellular
degradation through the lysosomal pathway. These effects
consequently rescued the mitochondrial dysfunction and
cellular defects caused by a-syn overexpression. To our knowl-
edge, this is the first study to employ aptamers to block the
aberrant cellular effects of the overexpressed a-syn in cells.
INTRODUCTION
Parkinson’s disease (PD) is one of the most prevalent forms of synu-
cleinopathies and neuropathologically characterized by the presence
of intracellular inclusions composed primarily of the protein a-synu-
clein (a-syn) in neurons1. a-syn is a small, natively unfolded protein
of 140 amino acids, and, in neurons, it is primarily found at the pre-
synaptic terminal.2 In the physiological state, a-syn is an intrinsically
disordered protein. The protein has the tendency to form oligomers
and aggregates, which are toxic and lie at the core of its pathological
function,3 although it is still in debate as to exactly which species
within the aggregation process may be more toxic.4 Importantly,
a-syn aggregates may propagate from cell to cell; once taken up by
recipient cells, they may act as seeds for further a-syn deposition
within acceptor cells.5,6 These pathogenic a-syn species may exert
their toxicity with mitochondrial damage, axonal transport dysfunc-
tion, inflammation, and other mechanisms. Thus, neutralizing the
pathogenic species or facilitating their clearance will have the poten-
tial to slow down or even halt PD progression.
Immunotherapy has emerged as a promising approach to target and
clear a-syn aggregate pathology in PD.7,8 In the past, efforts to iden-
tify agents that disrupt the a-syn aggregation yielded several potential
strategies, such as inhibiting the a-syn fibrillation process with small
molecules,9 lowering the protein level of a-syn by RNA interference,10
or enhancing cellular degradation processes.11 In recent years, immu-
notherapy is more appealing, as a-syn antibodies could prevent the
formation of pathogenic species, facilitate the clearance of already
formed species, and even shield pathogenic forms, consequently high-
lighting its neuroprotective or disease-modifying capabilities.6,12–14
However, due to the essence of antibody is protein, it has its own
weaknesses. For example, the antibodies are not easily accessible to
the intracellular target, significantly immunogenic, and more ther-
mally unstable, etc.15 Therefore, there is an urgent need to overcome
these weaknesses and find the antibody alternatives for application of
the immunotherapy in PD.
Aptamers are short, single-stranded DNA (ssDNA) or RNA mole-
cules that can bind to a wide range of target proteins with high affinity
and specificity.16 They are considered as “chemical antibodies” and
widely used as a substitute for antibodies. Compared with the conven-
tional antibodies, aptamers have their unique features. For example,
aptamers are neither immunogenic nor toxic molecules, because nu-
cleic acids are not typically recognized by the human immune system
as foreign agents; they have higher thermal stability and maintain
their structures over repeated cycles of denaturation/renaturation;
they can be easily generated by chemical synthesis, and can be easily
labeled and adjusted.15 Moreover, the aptamers can discriminate
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between different conformations of the same target protein.17 Since
the aptamer of Macugen was approved in 2004 by the US Food and
Drug Administration (FDA),18 the number of studies on the applica-
tions of aptamers has been rapidly increased. For the neurodegener-
ative diseases, a DNA aptamer, called A1, was selected, which binds to
b-Site amyloid precursor protein cleaving enzyme 1 (BACE1) with
high affinity and good specificity, consequently inhibiting BACE1 ac-
tivity and decreasing the production of beta-amyloid (Ab).19 Further-
more, a DNA aptamer that can specifically recognize and bind to Ab
oligomer was generated in 2012 and it could be a more efficient and
specific tool than antibodies in recognizing the Ab oligomer and pre-
venting Ab toxicity, as well as diagnosing Alzheimer’s disease (AD).20
As for the a-syn in PD, although several DNA aptamers against a-syn
have been generated,21,22 due to the limitations of selection, these ap-
tamers are in low affinity and specificity. As far as applying aptamers
to regulate a-syn toxicity, no investigation has been reported yet.
In this study, with the optimized SELEX on recombinant a-syn, we
obtained two aptamers (named as F5R1 and F5R2). The two aptamers
inhibited a-syn aggregation and targeted the cellular a-syn to
degradation in SK-N-SH cells and primary neurons, and rescued
the mitochondrial dysfunction and cell defects induced by a-syn
overexpression. To our knowledge, this is the first investigation
to employ aptamers to block the aberrant cellular effects of overex-
pressed a-syn in cells.
RESULTS
Selection of DNA Aptamers against a-Syn
In this study a glutathione-sepharose bead-based selection proced-
ure using immobilized glutathione S-transferase (GST)-a-syn was
Figure 1. a-syn Aptamers Were Selected through
SELEX
(A) Schematic illustration of the method used for a-syn
aptamer selection. GST-tagged a-syn was immobilized on
glutathione-sepharose beads. The ssDNA library was
incubated with the target beads for binding. Unbound ol-
igonucleotides were washed away, and the bound ones
were released by heating at 95C. The selected binders
were amplified by PCR with biotinylated primers. ssDNAs
were subsequently purified from the PCR product using
streptavidin-coated magnetic beads, resulting in an en-
riched DNA pool, which was used in the next SELEX
round. After the last round, the selected ssDNAs were
sequenced by deep sequencing. (B) The aptamer candi-
dates. After deep sequencing, the two sequences with
most frequently appearing were selected as the aptamer
candidates. (C) Aptamer binding specificity assay by dot
blotting. Five microgram samples (a-syn, GST, Ab42, BSA,
and three domains of a-syn) were respectively immobilized
onto the nitrocellulose membrane for binding of each
aptamer.
employed, since under this condition the target
protein can be kept in a near-free state,
excluding the extraneous interference such as
the electrophoresis from the gel-shift assay21 and conformational
restriction from the aptamer blotting assay22 (Figure 1A). After
the proteins were purified (Figure S1) an ssDNA library containing
a 40-nt random core sequence was passed through the immobilized
GST-a-syn on the beads. After 9 rounds of aptamer selection, we
sequenced each clone by deep sequencing. From the total read
counts, we obtained 11,019 sequences by removing the incorrect
sequences from deletion and/or insertion mutations during PCR
amplification and sequencing. The two sequences that most
frequently appear are selected as the aptamer candidates. Then
we chemically synthesized the aptamers (named as F5R1 and
F5R2) with 58 bases, in which the majority of the primer binding
regions were removed from the entire sequence, as these regions
might be less involved in protein binding (Figure 1B). To test
whether the aptamers have specificity against the a-syn protein,
we used aptamer blotting with GST, Ab1-42, and BSA as protein
competitors. The aptamers of F5R1 and F5R2 all only bound to
the a-syn protein (Figure 1C). Further dot blotting results showed
that the aptamers could bind with N- and C termini of a-syn (Fig-
ure 1C), suggesting that the N- and C termini of a-syn are respon-
sible for its interaction with the aptamers. Further, our competitive
ELISA tests indicated that the aptamers could inhibit the binding
of the antibodies to a-syn in a concentration-dependent manner
(Figure S2).
Binding Affinity of Selected Aptamers to a-Syn
To determine the binding affinities of the aptamers to a-syn, the ap-
tamers were used as a ligand to measure its interactions with a-syn
protein by biolayer interferometry (BLI). As shown in Figure 2A,
binding at five different a-syn concentrations, ranging from 10 to
www.moleculartherapy.org
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160 nM, readily fit a global model. The KD (equilibrium dissociation
constant [KD]) value of the aptamer F5R1 was 2.40 nM, with subsid-
iary fast-on kinetics (Kon) of 1.42 105 M1s1 and slow-off kinetics
(Koff) of 3.28  104 s1. Similarly, for aptamer F5R2, its KD value
was 3.07 nM, with fast-on kinetics (Kon) of 1.31  105 M1s1 and
slow-off kinetics (Koff) of 4.02 104 s1 (Figure 2B). These affinities
are substantially higher than those of the existing DNA aptamers
against a-syn (around 63 nM).22
Inhibiting the a-Syn Aggregation by Aptamers In Vitro
Previous studies showed that the antibodies that recognized the
N- or C terminus might inhibit the a-syn aggregation.6,13,23 We
hypothesized that the a-syn-specific aptamers could also inhibit
the self-assembly of a-syn. To test this hypothesis, thioflavin-T
(ThT) binding assay was performed and demonstrated that the for-
mation of amyloid fibrils was significantly reduced in the presence
of both aptamers, and F5R1 showed better inhibition effect than
F5R2 (Figure 2C). Furthermore, the dose-dependent inhibition of
F5R1 was assayed, and it showed that F5R1 was efficient at an
excess of 10:1 molar ratio (F5R1:a-syn) but was less efficient at
5:1 ratio (Figure 2D). Additionally, transmission electron micro-
scopy (TEM) analysis was performed on the samples from the
ThT experiment. While the fibrils formed by a-syn alone and
the presence of random DNA sequence were large, broad, and
had a ribbon-like shape with large quantity (Figures 2E and 2F),
only a few short fibrils were detected in the presence of aptamers
(Figures 2G and 2H). These results are highly correlated with the
results of the ThT assay.
CADY-Mediated Aptamer Delivery into SK-N-SH Cells
Previous studies showed that the peptide carrier CADY could form
stable complexes with nucleic acids and improved their delivery in
cultured cells.24 Thus, we tried to use CADY peptide as a carrier to
deliver the aptamers into the cells. First, we confirmed that the
aptamers were completely associated with CADY when the molar
ratio of CADY/aptamer was more than 20 and that CADY could
protect the aptamer from degradation by serum nuclease (Fig-
ure S3). Next, a fixed concentration (20 nM) of the aptamers
labeled with Alexa594 was complexed with CADY at a CADY/
aptamer molar ratio of 40:1, and the confocal microscopy showed
that the aptamers were delivered into cells with high efficiency
(Figure 3A). To further confirm aptamer uptake, Alexa594-labeled
aptamers with a fixed concentration of 20 nM were incubated with
CADY at different CADY/aptamer molar ratios, ranging from 0:1
to 80:1 for 4 hr, then the internalization was monitored by fluores-
cence-activated cell sorting (FACS) (Figures 3B and 3C). The data
showed that the fluorescence intensity in cells was in a dose-depen-
dent manner, suggesting that the aptamer uptake efficiency
was directly related to the molar ratio of the CADY/aptamer.
For the rest of the experiments in this study, unless otherwise
noted, for delivery of aptamers into SK-N-SH cells, the molar ratio
of CADY/aptamer at 40:1 was used. Additionally, we confirmed
Figure 2. Binding Affinity of the Selected Aptamers to a-syn and Their In Vitro Inhibition of a-syn Aggregation
(A and B) BLI analysis of the aptamers F5R1 (A) and F5R2 (B) binding to a-syn, respectively. The a-syn concentrations were 10, 20, 40, 80, and 160 nM, respectively. (C)
Kinetic analysis of the aggregation of a-syn in the presence of aptamers using ThT (molar ratio between the a-syn and aptamer is 1:10). (D) Dose-dependent inhibition effect of
aptamer F5R1 on a-syn aggregation. The reaction mixtures were incubated at 37C with constant agitation (1,000 rpm) for 3 days and the rate of fibrillogenesis was
monitored using the thioflavin T (ThT) fluorescence assay. (E–H) TEM images of a-syn fibrils with aptamer F5R1. a-syn alone (E), a-syn with random DNA sequence (F), F5R1
(G), and F5R2 (H). Scale bar, 200 nm.
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Figure 3. Aptamers Were Delivered by CADY into Cultured SK-N-SH Cells and Inhibited a-syn Aggregation
(A) The CADY/Alexa594-labeled F5R1 complexes were formed at molar ratio of 20/1 and overlaid onto SK-N-SH cells for 4 hr at 37C. Cells were then washed and the
fluorescence was detected by confocal laser microscopy. Scale bars, 25 mm. (B and C) The CADY/F5R1 complexes were formed at different molar ratios and overlaid onto
(legend continued on next page)
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that aptamer uptake could not cause cytotoxicity in the SK-N-SH
cells (Figure S4).
Aptamers Inhibited a-Syn Aggregation in SK-N-SH Cells
To further investigate whether aptamers also can recognize intracel-
lular a-syn and block its aggregation in living SK-N-SH cells, first, the
aptamers labeled with Alexa Flour-594 were delivered into EGFP-
a-syn overexpressing cells, and the confocal laser scanning data
showed that both F5R1 and F5R2 were co-localized with a-syn in
cytoplasm (Figure 3D). We next confirmed that aptamers directly
bound to a-syn in cells with a pull-down assay using biotinylated ap-
tamers as affinity capture agents (Figure 3E), whereas no binding was
observed in the random DNA sequence group.
Next, we employed a protein-fragment complementation assay
(PCA)25–27 to investigate whether the aptamers could inhibit the for-
mation of a-syn aggregates in cells (Figure 3F). Twenty-four hr after
co-transfection of the a-syn-hGLucN and a-syn-hGLucC constructs
into the SK-N-SH cells, the reconstituted luciferase activity was
almost 2-fold as high as that in control cells. However, the pre-treat-
ment with the aptamers of F5R1 or F5R2 prevent this increase in
luciferase activity, respectively. In contrast, the random DNA
sequence pre-treatment did not show such an effect (Figure 3G).
Additionally, aptamers at various concentrations (from 1 to
20 nmol/L) complexed with CADY in the pre-treatment caused the
decrease in luciferase activity in an aptamer concentration-dependent
manner (Figure S5). To exclude the possibility that the decreased
luciferase activity was due to the aptamers delivered into the cells
downregulating the a-syn level, we further confirmed that the intra-
cellular protein level of a-syn-hGLuN and a-syn-hGLuC did not
show any change between the indicated groups (Figure 3H). Collec-
tively, these data suggested that the aptamers inhibited the a-syn olig-
omerization in cells, and, for the rest of the experiments regarding
aptamer pre-treatment to the SK-N-SH cells, the aptamer concentra-
tion of 20 nmol/L was used.
Aptamers Protected against a-Syn-Induced Mitochondria
Dysfunction
Previous studies showed that aggregated a-syn was more strongly
associated with mitochondria,28 and these aggregates augmented
oxidative stress and suppressed mitochondrial and cellular func-
tions.29 So we further tested whether these aptamers could block
the association of a-syn with mitochondria and consequently sup-
press the oxidative stress. Figure 4A shows, in non-treated or random
DNA sequence-treated groups, intense co-localization of a-syn
(green) with the mitotracker (red) was detected. However, in the ap-
tamer treatment groups, less mitochondrial localization of a-syn was
observed. Further evidence for mitochondrial association of a-syn
was achieved by immunoblotting (Figures 4B and 4C). These results
suggested that the aptamers of F5R1 and F5R2 could block the asso-
ciation of a-syn with mitochondria since the aptamers could inhibit
the a-syn aggregation in cells.
Next, we evaluated intracellular reactive oxygen species (ROS) levels
and D4m in SK-N-SH cells by DCF-DA and JC-1 staining. The ROS
level increased about 2-fold in the a-syn overexpression group
compared with the blank vector group. However, the F5R1 or F5R2
pre-treatment almost completely eliminated the increase of ROS level
by a-syn. The aptamer effects on ROS were not observed in the
random DNA sequence pre-treatment group (Figures 4D and 4E).
Similarly, aptamers of the F5R1 and F5R2 also could rescue the mem-
brane potential decline induced by a-syn (Figures 4F and 4G). Collec-
tively, F5R1 and F5R2 could prevent the a-syn-induced increase in
ROS and decrease in mitochondrial membrane potential and, there-
fore, potentially rescue the mitochondrial dysfunction caused by
a-syn overexpression.
Aptamers Induced Lysosomal Degradation of a-Syn
Since previous studies indicated that aptamer could effectively target
the protein to intracellular degradation,30 we hypothesized that F5R1
and F5R2 delivered into the cells could induce the a-syn degradation.
To address our hypothesis, pcDNA3.1-a-syn constructs were trans-
fected into the SK-N-SH cells with or without aptamer pre-treatment,
and we found that, after the transfection for 24 hr, regardless of the
aptamer pre-treatment, the a-syn protein level did not show any sig-
nificant change (Figures 5A and 5B); interestingly, 48 hr after the
transfection, both F5R1 and F5R2 pre-treatments resulted in a signif-
icant decrease in a-syn level when compared to the untreated groups,
whereas the random DNA sequence pre-treatment did not have such
an effect (Figures 5C and 5D). These results suggested that the a-syn
aptamers of F5R1 and F5R2 effectively targeted a-syn to intracellular
degradation.
Next, because a previous report showed that a-syn underwent degra-
dation in lysosomes once perturbed by antibodies,14 we hypothesized
that F5R1 and F5R2 delivered into the cells could induce the a-syn
SK-N-SH cells for 4 hr at 37C. Cells were then washed and trypsinized, and the fluorescent cells were counted by flow cytometry. Results are reported for 100,000 cells
(n = 5). (D) SK-N-SH cells were transfected with EGFP-a-syn constructs or EGFP vector as control. After 6 hr, the aptamers of F5R1 and F5R2 labeled with Alexa594
complexed with CADY were used to treat these cells, respectively. The EGFP-a-syn co-localization with F5R1 or F5R2 was detected by confocal laser microscopy. Arrows
showed the co-localization spot. Scale bar, 10 mm. (E) SK-N-SH cells were pre-treated with CADY/biotinylated-aptamer complexes (aptamer at 100 nM and the CADY/
aptamer molar ratio at 40; random DNA sequence served as the control), and then transfected with pcDNA3.1-a-syn for a-syn overexpression. Streptavidin magnetic beads
were incubated with protein lysate overnight at 4C. Samples were resolved by using SDS-PAGE and a-syn was detected by western blotting. (F) Principle of bioluminescent-
protein complementation assay based onG. princeps luciferase. (G) SK-N-SH cells with/without CADY/aptamer complex pre-treatment were co-transfected with constructs
of a-syn-hGLucN and a-syn-hGLucC. After transfection for 24 hr, the luciferase activity from protein complementation wasmeasured in an automated plate reader at 480 nm
with substrate coelenterazine (20 mM). Data are presented as the mean ± SD (one-way ANOVA) ***p < 0.001 compared with control group (n = 6); ###p < 0.001 compared
with a-syn-hGLuN/C group. (H) SK-N-SH cells with/without CADY/aptamer complex pre-treatment were transfected with constructs of a-syn-hGLucN and a-syn-hGLucC
to show the expression of each protein. Immunoblots were probed with antibody against a-syn.
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Figure 4. The Aptamers of F5R1 and F5R2 Prevented a-syn Binding to Mitochondria and Rescued Mitochondrial Dysfunction
(A) After aptamer pretreatment, SK-N-SH cells were transfected with EGFP-a-syn cDNA. 24 hr after transfection, cells were stained by mitotracker (red) for marking
mitochondria. Merge shows overlaid images of mitochondria and EGFP-a-syn. Nuclei were counter-stained with Hoechst (blue). Scale bar, 20 mm. (B) After aptamer
pretreatment, SK-N-SH cells were transfected with pCDNA3.1-a-syn for overexpression of a-syn. Twenty-four hr after transfection, the mitochondria in the cells were
isolated, and the a-syn associated with mitochondria was measured by immunoblotting. The random DNA sequence group was used as a negative control. After 24 hr,
mitochondria were purified, and its purity was tested by immunoblotting the mitochondria extracts against a mitochondrial marker, VDAC1, and a cytoplasmic marker,
b-actin. VDAC1 also serves as mitochondrial loading control. (C) Quantitative analysis of the protein level of a-syn within mitochondria. Data are presented as the mean ± SD
(one-way ANOVA) **p < 0.01 compared with vector group; #p < 0.5 compared with a-syn overexpressing group (n = 3). (D–G) Cells were treated as in (B), and the mito-
chondrial function was assayed 24 hr post-transfection. (D) The Mitochondrial reactive oxygen species (ROS) were visualized by DCF-DA (scale bar, 50 mm). (E) Quantitative
(legend continued on next page)
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degradation by lysosomes. To test this hypothesis, we examined the
effect of a specific inhibitor of lysosomes (NH4Cl) and a proteasome
inhibitor (MG132) on a-syn degradation, respectively. As shown in
Figures 5E and 5F, the drug of NH4Cl significantly inhibited the effect
of the aptamers of F5R1 and F5R2 on a-syn degradation. However,
the proteasome inhibitor MG132 exerted no significant effect on
a-syn degradation. Taken together, we provided evidence to support
that the a-syn aptamers of F5R1 and F5R2 can effectively target a-syn
to intracellular degradation, likely through the lysosomal pathway.
Aptamers Reduced the Cytotoxicity Caused by a-Syn
Overexpression
Because F5R1 and F5R2 could reduce the a-syn oligomerization,
preserve mitochondrial function, and facilitate the cellular a-syn
analysis of DCF-DA fluorescence intensity by high-content screening in SK-N-SH cells. Data are presented as the mean ± SD (one-way ANOVA) ***p < 0.001 compared with
vector group; ###p < 0.001 compared with a-syn overexpression group (n = 6). (F) D4m detected with JC-1 in transfected SK-N-SH cells. (G) Quantitative analysis of red
fluorescence intensity by high-content screening in SK-N-SH cells. Data are presented as the mean ± SD (one-way ANOVA) ***p < 0.001 compared with vector group;






Figure 5. The Aptamers of F5R1 and F5R2 Enhanced Lysosomal Degradation of a-syn and Rescued the Cell Defects
(A)SK-N-SHcellspre-treatedwithF5R1,F5R2or randomDNAsequencewere transfected thea-synor vector control vectorsand incubated for 24hr. Theextractswereseparated
by SDS-PAGE and blotted onto PVDFmembrane. The membrane was blocked and probedwith the a-syn specific polyclonal antibody. b-actin served as the loading control. (B)
Quantitative analysis of the total protein level of a-syn from (A). (C) SK-N-SH cells were similarly treated as in (A) except for incubation time (48 hr). The cell extracts were im-
munoblottedwith the a-syn polyclonal antibody. b-actin served as the loading control. (D) Quantitative analysis of the total protein level ofa-syn from (C). Data are presented as the
mean ± SD (one-way ANOVA) ***p < 0.001 compared with vector group; ##p < 0.01 compared with a-syn overexpression group (n = 3). (e) Cells were treated similarly as in (C),
except for treated with NH4Cl or MG132 after 6 hr of transfection. The cell extracts were immunoblotted with the a-syn polyclonal antibody. (F). Quantitative analysis of the total
protein level of a-syn from (E). Data are presented as themean± SD (one-way ANOVA) **p < 0.01 compared with a-syn+F5R1 group; ###p < 0.001 compared with a-syn+F5R2
group (n = 5). (G andH)Cells were treated similarly as in (E), Forty-eight hr after transfection, the cell viabilitywas assessedbyMTT assay (G) and LDHassay (H). Data are presented
as the mean ± SD (one-way ANOVA) ***p < 0.001 compared with vector group; ###p < 0.001 compared with a-syn overexpression group (n = 6).
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Figure 6. Aptamers were Delivered into Cultured Primary Neurons and Rescued the Cell Toxicity Caused by a-syn Overexpression
(A) Alexa594-labeled aptamer F5R1 (10 nM) was complexed with CADY peptide (the molar ratio of CADY/F5R1 at 20), and then incubated with the 3 DIV (day in vitro) primary
neurons for 2 hr. The fluorescence was detected by confocal laser microscopy (scale bar, 25 mm). The neurons are stained with MAP2 in green. (B) The 3 DIV primary neurons
(legend continued on next page)
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degradation, we then tested whether F5R1 and F5R2 could reduce the
cytotoxicity and rescue the cell defects with 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydro-
genase (LDH) release assays. It showed that overexpression of
a-syn resulted in a 30% decrease in cell viability compared with the
blank vector group. However, the F5R1 or F5R2 pre-treatment could
significantly increase the cell viability compared with the a-syn-alone
group. Further, the minimal effective concentration to rescue the cell
defects was estimated at 15 nM (Figure S6). In contrast, such an effect
was not observed in the random DNA sequence-treatment group
(Figure 5G). Similarly, these two aptamers also decreased LDH release
in SK-N-SH cells as compared to the a-syn-only group, and the
random DNA sequence treatment had no such effect (Figure 5H).
These data collectively demonstrated that the a-syn aptamers of
F5R1 and F5R2 were able to rescue cell dysfunction.
Aptamers Delivered into Primary Neurons Induced a-Syn
Degradation and Rescued the Mitochondria Dysfunction and
Cell Defects in Primary Neurons
To further investigate the effect of aptamers on reducing a-syn
toxicity in primary neurons, primary neurons with aptamer pre-treat-
ment were infected with lentiviral particle-containing LV-a-syn, then
the cellular a-syn protein level, mitochondria function, and primary
neuronal viability were measured.
First, we confirmed that that aptamers could be delivered into the pri-
mary neurons (Figure 6A) by Alexa594-labeled aptamer F5R1 uptake
assay. Next, to further test whether aptamers also can induce a-syn
degradation, the primary neurons at 3 DIV (days in vitro) were
treated with the CADY/aptamer complex for 2 hr and then infected
with the LV-a-syn virus. At 8 DIV, total neuronal proteins were ex-
tracted, and the immunoblotting showed that, as we expected, both
F5R1 and F5R2 could reduce the a-syn protein level more than
50%, whereas the random DNA sequence had no such effect (Figures
6B and 6C).
To examine the protective effects of F5R1 and F5R2 on the mitochon-
drial function, the primary neurons were treated similarly as in Fig-
ure 6B, and the mitochondrial transmembrane potential (D4m)
was detected by D4-sensitive probe TMRM. As shown in Figures
6D and 6E, a decrease in TMRM intensity in the a-syn overexpression
group was observed compared with the vector control group.
Notably, both F5R1 and F5R2 treatments could suppress the decline
in TMRM fluorescence, and the random DNA sequence had no such
effect. These results suggested that the decrease in membrane poten-
tial in a-syn overexpressing primary neurons could be prevented by
the aptamers. Next, the viability and apoptosis of primary neurons
with the aptamer treatment were measured as a marker of cellular
functions. Figures 6F and 6G showed that a-syn overexpression in
the primary neurons reduced cell viability and increased cell
apoptosis, and the effects were reversed by F5R1 or F5R2, but not
random DNA sequence.
Aptamers Rescued the Neurite Morphology Change Caused
by a-Syn
It was reported that overexpression of a-syn resulted in reduced neu-
rite extension in neuronal cells, which is a detrimental factor for neu-
rite integrity.31,32 Here, we investigated whether aptamers could
rescue the impairment of neurite outgrowth caused by a-syn. The pri-
mary neurons at 3 DIV were first treated by CADY/aptamer complex
and then they were infected with the LV-a-syn virus. After a 5-day
culture, the single neurite length was measured. The mean single neu-
rite length (60 mm) was significantly reduced in the neurons overex-
pressing a-syn as compared with the blank vector group (100 mm).
On the other hand, the neurite length in the F5R1- (93 mm) and
F5R2- (89 mm) treated groups were obviously longer than that in
the a-syn overexpression group, whereas there was no statistically sig-
nificant difference between the randomDNA sequence group and the
a-syn overexpression group (Figure 7). These results implied that
a-syn aptamers rescued the impairment of neurite outgrowth caused
by a-syn and stabilized neurite morphology.
DISCUSSION
This study demonstrated that a-syn aptamers were able to inhibit
a-syn aggregation and promote clearance of a-syn in human a-syn
overexpressing cell lines and primary neurons. Aptamers of F5R1
and F5R2, two 58-base-long nucleotides, were selected under the opti-
mized SELEX process and demonstrated a high affinity and specificity
to bind to a-syn against its N- and C termini. These aptamers were
efficient in reducing a-syn aggregation in vitro and in cells and further
targeted the a-syn to intracellular degradation through the lysosomal
pathway, consequently rescuing the mitochondrial dysfunction and
cellular defects caused by a-syn overexpression (Figure 8). To our
knowledge, it is the first to employ the aptamers to block the aberrant
cellular effects of overexpressed a-syn in cells.
SELEX is a common process involving the progressive isolation of
highly selective ssDNA/RNA from a combinatorial single-stranded
oligonucleotide library. Previously, although several aptamers
to a-syn have been selected,21,22 their affinities are relatively low
were treated with CADY/aptamer complex for 2 hr as in (A), then were infected with LV-a-syn cDNA. At 8 DIV, total neuronal proteins were extracted, and the human a-syn
was detected by immunoblotting. b-actin was examined as a loading control. (C) Quantitative analysis of a-syn level from (B). Data are presented as the mean ± SD (one-way
ANOVA) ***p < 0.001 compared with vector group; ###p < 0.001 compared with a-syn overexpression group (n = 6). (D) The primary neurons were treated as described in
(B). At 8 DIV, the mitochondrial transmembrane potential (D4m) was detected byD4m-sensitive probe TMRM under confocal laser microscopy. ZsGreen was used to confirm
the virus vector working well in neurons (scale bar, 100 mm). (E). Reactive fluorescence intensity of TMRM in mitochondria from 3 coverslips was quantitative analyzed. Data
are presented as the mean ± SD (one-way ANOVA) ***p < 0.001 compared with vector; ###p < 0.001 compared with a-syn overexpression group (n = 3). (F and G) Primary
neurons were treated as described in (B). At 8 DIV, cell viability and cytotoxicity were detected in primary neurons with the MTT (F) and LDH (G) assays. Data are presented as
the mean ± SD (one-way ANOVA) ***p < 0.001 compared with vector; ###p < 0.001 compared with a-syn overexpression group (n = 6).
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(the KD value was around 63 nM), probably because of the extraneous
inferences during the selection process, such as the a-syn conforma-
tional restriction from the membrane blotting22 and the electropho-
resis from the gel-shift assay.21 In this study, the selection process
was optimized: the glutathione-sepharose bead-based selection pro-
cedure using immobilized GST-a-syn was employed since, under
this condition, the target protein could be kept in a near-free state
(Figure 1A). Consequently, the selected aptamers of F5R1 and F5R2
showed higher affinity (their KD value were 2.40 nM and 3.07 nM,
respectively).
Although in past decades the mechanisms of a-syn aggregation have
been extensively studied, a consensus view of the aggregation mech-
anism is still elusive. Interestingly, the NMR residual dipolar coupling
(RDC) data suggested that there exists long-range interaction be-
tween the N- and C termini in the a-syn.33 Under conditions that in-
crease the long-range interactions, the a-syn aggregation is enhanced;
however, conditions that weaken such interactions are associated with
reduced aggregation.34,35 Thus, it seems that long-range interactions
may facilitate the a-syn aggregation process.36 In such scenarios,
since the aptamers may bind with the N- and C termini of a-syn
and potentially shield these two fragments, the long-range interaction
within a-syn probably would be weakened or blocked, so its aggrega-
tion is inhibited. Certainly, more structure-function data are still
needed to support this hypothesis.
The major limitation of the therapeutic application of nucleic acids
is the poor permeability of the cell membrane and their restricted
biodistribution.24,37,38 As a secondary amphipathic peptide derived
from PPTG1 peptide, CADY was used to rapidly deliver the siRNA
into the challenging cell lines (including primary neurons) and,
consequently, a long-term silencing response was achieved, with
60% knockdown of the target gene after 5 days.24 In this study, it
was shown that the CADY was thoroughly associated with the ap-
tamers with a molar ratio >20, as already reported for other nonco-
valent peptide carriers.39 Furthermore, the CADY peptide could
protect aptamers from serum degradation and efficiently deliver
the aptamers into the SK-N-SH cells and primary neurons with
no cytotoxicity.
Currently, although it is not clear which form of the a-syn protein is
more cytotoxic, massive neuropathological, biochemical, and genetic
evidence have shown that a-syn oligomers and aggregates are critical
for the death of dopaminergic neurons and the progression of
PD.3,4,40 Particularly, previous studies showed that the aggregated
a-syn bound to the mitochondria of a-syn overexpressing SHSY cells,
resulting in mitochondrial impairments via increasing ROS and
decreasing D4m,
29 which plays a role in death of the dopaminergic
neurons in PD.41,42 In this study, the data demonstrated that both
F5R1 and F5R2 aptamers could recognize cellular a-syn, block its ag-
gregation in cells, and inhibit binding of a-syn to mitochondria.
Functionally, the mitochondrial dysfunction was rescued by the ap-
tamer treatment. These data strongly support the previous findings
in co-localization of a-syn within the mitochondria of a-syn overex-
pressing cells and functional significance for a-syn association with
mitochondria.
In previous studies, the DNA aptamer against ErbB-2 effectively tar-
geted the protein to intracellular degradation in lysosomes in cells and
animals.30 More passive administration of a-syn antibodies to cell
and animal models have demonstrated that the antibody directed
a-syn protein clearance via the lysosomal pathway.8,12,14 In agree-
ment with these findings, our data showed that the levels of a-syn
in cell lysate were decreased after aptamer treatment, which was
possibly attributed to the aptamer targeting a-syn to intracellular
degradation through the lysosomal pathway.
A B
Figure 7. Aptamers Rescued the Neurite Morphology Change of the Primary Neuron Infected with LV-a-syn
(A) The aptamers of F5R1 and F5R2 (10 nM each) was complexed with CADY peptide (the molar ratio of CADY/F5R1 or CADY/F5R2 at 20) and incubated with primary
neurons at 3 DIV for 2 hr, then were infected with LV-a-syn vectors. At 8 DIV, an immunocytochemistry of the primary neurons was performed. Neurons were stained against
MAP2, and the random DNA sequence group served as the negative control (scale bar, 200 mm). (B) Quantification of single neurite lengths of primary neurons. Data are
presented as the mean ± SD (one-way ANOVA) ***p < 0.001 compared with vector; ###p < 0.001 compared with a-syn overexpression group (n = 6).
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In summary, aptamers against the protein of a-syn were selected, and
we demonstrated that these aptamers inhibited a-syn aggregation and
further targeted the cellular a-syn to degradation through the lyso-
somal pathway, consequently rescuing themitochondrial dysfunction
and cell defects in the a-syn overexpressing SK-N-SH cells and pri-
mary neurons. With future experiments in animals, these aptamers
could be developed as a unique and potential strategy to target
a-syn in the context of PD therapy.
MATERIALS AND METHODS
Preparation of a-Synuclein
The a-syn gene was subcloned into the pGEX-4T-1 vector, and the
fusion protein GST-a-syn was expressed in Escherichia coli BL21
(DE3), which was induced by the addition of 0.2 mM isopropyl-1-
thiob-D-galactopyranoside (IPTG) at 28C. The cells were disrupted
by sonification, and the supernatant was collected by centrifugation
(18,000 g, 10 min, 4C). Then the fusion protein GST-a-syn was pu-
rified on glutathione-sepharose 4B according to the manufacturer’s
instructions (GE Healthcare, Boston, MA). The purified GST-fusion
proteins were desalted on Vivaspin 6 column from GE Healthcare,
followed by dialysis into binding buffer (PBS, 1 mM MgCI2, pH
7.4) to remove the free glutathione. To cleave the GST tag from the
fusion protein and recover the proteins of a-syn and GST separately,
thrombin was used for cleavage with on-column settings according to
the manufacturer’s instructions (GE Healthcare, Boston, MA).
Design of a DNA Library
The starting point of the selection process was a 40-nt completely
random ssDNA library (50-GATGTGGTAGGTGATCGAGTG-N40-
GCAGGATCCATCCACCTCTA-30) that was chemically synthesized
by Invitrogen (Carlsbad, CA) and high-performance liquid chroma-
tography (HPLC) purified. A 20-mer primer-binding region was
flanking the randomized region at both ends, respectively. To fold
the structure, the synthesized oligonucleotides were heated at 95C
for 3 min and then gradually cooled to 25C at a rate of 5C per
min in PBS.
Selection of Aptamers
Iterative rounds of aptamer selection and amplification during the
systematic evolution of ligands by exponential enrichment (SELEX)
process were modified from previous protocols.43 Primers that anneal
to the 50-and 30-sequences flanking the random core region used dur-
ing the selection were: Apt_50, GATGTGGTAGGTGATCGAGTG,
and Apt_30, TAGAGGTGGATGGATCCTGC; in non-biotinylated
and 50-biotinylated forms respectively (HPLC-purified). A 1 nmol
aliquot of DNA library was incubated with GST-a-syn immobilized
on glutathione-sepharose beads in PBS for 45 min at 4C. The
unbound DNA was separated and removed by centrifugation at
500 g for 5 min. The bound sequences were released by heating to
95C for 2 min and PCR-amplified using biotinylated primers.
A 100 mL aliquot of the PCR product containing enriched biotinylated
double-stranded DNA was equilibrated with 100 mL of 2 
binding and washing buffer (10 mM Tris-HCI, 1 mM EDTA,
2 M NaCI, pH7.5) and 1 mg of M-280 streptavidin magnetic beads
(Invitrogen, Carlsbad, CA) for 10 min. By magnetic separation,
non-biotinylated ssDNA was recovered and dissociated from the
immobilized complementary biotinylated strand using 100 mL of
150 mM NaOH for 5 min. Then, nine cycles were performed with
counter selection using immobilized GST magnetic beads at rounds
two and five. During the last round of SELEX, the recovered DNA
molecules were PCR amplified using non-biotinylated primers and
subjected to be sequenced by deep sequencing (WuXi AppTec,
Shanghai, China).
Dot Blotting
5 mg proteins of BSA, Ab1-42, GST, a-syn, and its three truncates, N
terminus (residues 1–60), NAC domain (residues 61–95), and C ter-
minus (residues 96–140) (synthesized by Thermo Fisher Scientific,
Waltham, MA), were respectively immobilized onto nitrocellulose fil-
ter membrane. After blocking with 0.5% fat-free milk in Tris-buffered
saline Tween-20 (TBST) for 1 hr, the membrane was incubated with
100 nM aptamer labeled with FITC overnight at room temperature.
Figure 8. The Aptamers Exert Neuroprotective Effects against a-syn-
Induced Cell Dysfuction by Inhibiting a-syn Aggregation and Promoting
a-syn Degradation through Lysosomes
The selected two aptamers possessed the high affinity and specificity to bind to the
N- and C termini of a-syn and inhibited the a-syn aggregation process in vitro (A).
After these aptamers were delivered into the cells, they were efficient in reducing
a-syn aggregation in vivo, and further targeted the a-syn to intracellular degradation
through lysosomal pathway, consequently rescuing the mitochondrial dysfunction
and cellular defects caused by a-syn overexpression (B).
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The membrane was washed three times with TBST and then incu-
bated with FITC antibody that was labeled with HRP (Takara, Japan)
for 4 hr. Dots were visualized using enhanced chemiluminescence.
Evaluation of the Aptamer Binding Affinity by BLI
The BLI experiments were performed on a FortéBio (Menlo Park, CA)
Octet QK biosensor using streptavidin (SA) sensors to determine bind-
ing affinity of aptamers against a-syn. Assays were performed in
96-well microplates at 25C. All volumes were 200 mL. After loading
biotinylated aptamers onto SA sensors, a baseline was established in
the binding buffer (50 mMTris/100 mMNaCl, pH 7.0) prior to moni-
toring the association at various a-syn concentrations. Dissociation
subsequently was measured in buffer only. The KD of aptamer was
calculated with Octet software (version 8.0) from the association and
dissociation curve of the aptamer binding with a-syn.
ThT Fluorescence Assay of Fibril Formation In Vitro
a-syn was dissolved to a concentration of 360 mM (around 5 mg/mL)
in the assembly buffer (50 mMTris/100 mMNaCl, pH 7.0). The a-syn
protein was mixed with or without aptamer at a 1:10 ratio, the reac-
tion mixtures were incubated at 37C with constant agitation
(1,000 rpm) as described by Luk et al.,44 and the rate of fibrillogenesis
was monitored using the thioflavin T (ThT) fluorescence assay (exci-
tation at 450 nm, 2.5 nm slit, and emission at 480 nm, 5 nm slit).
ThT was added to a 500-fold diluted sample, and fluorescence
was measured using a fluorometer from PerkinElmer EnVision
(Waltham, MA).
Transmission Electron Microscopy Assay
Samples (10 mL) from the a-syn ThT fluorescence assay were placed
on 400-mesh copper grids covered by carbon-stabilized Formvar film
(SP I Supplies, West Chester, PA). After 2 min, excess fluid was
removed and the grids were negatively stained with 10 mL of 2% ura-
nyl acetate solution for 2 min. Finally, excess fluid was removed and
the samples were viewed by a JEM electron microscope operating
(Tokyo, Japan) at 80 kV.
Lentiviral Vector Production
For lentiviral expression of a-syn in primary neurons, the human
a-syn gene was cloned into the lentiviral vector pLVX-IRES-
ZsGreen1 to generate pLVX-IRES-ZsGreen1/a-syn. Lentiviral parti-
cles were generated by PEI-mediated co-transfection of HEK293T
cells with pLVX-IRES-Green1/a-syn (or empty pLVX-IRES-Green1,
as control), psPAX2 (Packaging plasmid), and pMD2G (Envelope
plasmid). Virus (LV-a-syn) was collected after 72 hr, and titers up
to 3–4  106 infectious units/mL were obtained.
Cell Culture, CADY-Mediated Aptamer Treatment, and Protein
Overexpression
Human neuroblastoma SK-N-SH cells were cultured in 6-well plates
with DMEM with 10% FBS, 50 U/mL penicillin, and 50 mg/mL
streptomycin. All media were from GIBCO (VA). CADY peptide
(Ac-GLWRALWRLLRSLWRLLWRA-cysteamide, 1 mg) was synthe-
sized by Thermo Fisher Scientific (Waltham, MA) and dissolved into
10 mL dimethylsulfoxide (DMSO, Sigma, St. Louis, MO) rapidly,
and then DNase-free water was added to get the CADY solution at
2 mg/mL (0.3 mM) with sonication for 10 min. To obtain CADY/
aptamer complexes, naked aptamer (5 mmol/l stock solution) was
mixed with CADY peptide (100 mM stock solution) and incubated
for 37C for 30 min. For aptamer delivery into SK-N-SH cells, the
cells were overlaid with 200 mL preformed complexes (20 nM ap-
tamer; the CADY/aptamer molar ratio at 40) for 5 min, and then
400 mL of DMEM was added. After incubation for 2 hr, 1 mL of me-
dium containing 16% FBS was added to obtain a final FBS concentra-
tion of 10%. For a-syn overexpression, 3 mg pcDNA3.1 blank vector,
pcDNA3.1-a-syn, pEGFP-N1 blank vector, or pEGFP-N1-a-syn
were diluted in 1 mL of DMEM separately. Then, 9 mg polyethylenei-
mine (PEI; Polysciences, Warrington, PA) was added to the DNA so-
lution. The PEI/DNA solution was incubated at 37C for 30 min to
allow the PEI and DNA to form a nanoparticle complex. The pre-
prepared PEI/DNA solution was then added to the plate well, and
SK-N-SH cells were grown in the transfection mixture for another
24 hr or 48 hr at 37C and in 5% CO2.
Primary neuronal cultures were prepared from brains of C57BL/6
mouse embryos (days 14.5–15.5). All experiments were authorized
by the Institutional Animal Care and Use Committee of the Capital
Medical University of Science and Technology (approval No. AEEI-
2016-057) and performed according to the NIH Guide for the Care
and Use of Laboratory Animals. Briefly, dissociated neurons were
plated onto poly-L-lysine (Sigma, St. Louis, MO) -coated coverslips
or dishes at 20,000-40,000 cells/cm2 or 70,000–100,000 cells/cm2,
respectively. The cells were cultured in Neurobasal medium (GIBCO)
supplemented with l-glutamine (0.5 mM) and 50 B27 supplement
(for a final concentration of 1 ; GIBCO). For aptamer delivery
into primary neurons, after 3–4 days of cell culture, half of the me-
dium was discarded and the CADY/aptamer complexes (aptamer at
10 nM and the CADY/aptamer molar ratio at 20) were added to
the dishes. 2 hr later, the primary neurons were infected with lenti-
virus overexpressing a-syn (LV-a-syn) or control lentivirus.
Serum Nuclease Protection Assay
Naked aptamer (100 fmol) or the CADY/aptamer complexes formed
as described earlier were incubated in DMEM containing 50% FBS at
37C for 24 hr. Proteinase K (200 mg/mL) was added into the mixture
and incubated for 1 hr at 37C to stop the reaction and digestion of
CADY peptide. The aptamer was extracted with phenol:chloroform
and analyzed on a 1.5% agarose gel.
Biotinylated Aptamer Pull-Down Assay
SK-N-SH cells were pre-treated with CADY/biotinylated-aptamer
complexes (aptamer at 100 nM and the CADY/aptamer molar ratio
at 40; random DNA sequence, ATCGAGTG-N40-GCAGGATCCA,
served as control) and then transfected with pcDNA3.1-a-syn for
a-syn overexpression. After transfection for 18 hr, cells were washed
three times with PBS and lysed (10 mmol/L Tris-HCl pH 7.5;
200 mmol/L NaCl; 5 mmol/L EDTA acid; 0.1% Triton X-100;
mammalian protease inhibitors). Streptavidin magnetic beads
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(10 mL; Invitrogen, Carlsbad,CA) were incubated with 500 mg of pro-
tein lysate overnight at 4C. The streptavidin beads were washed three
times in BW buffer (5 mMTris-HCl, 0.5 mMEDTA, 1MNaCl). Sam-
ples were resolved by using SDS-PAGE and transferred to a polyviny-
lidene fluoride (PVDF) membrane (Millipore, Billerica, MA). The
membrane was blocked with 3% (w/v) milk, and an a-syn-specific
mouse polyclonal antibody (BD Biosciences, Franklin Lakes, NJ)
was used to detect a-syn. After three washing steps, an HRP-labeled
secondary antibody (Takara, Japan) was used for colorimetric
staining.
Isolation of Mitochondria
Mitochondria were isolated from SK-N-SH cells using the Mitochon-
dria/Cytosol Fractionation Kit (Applygen Technologies, Beijing,
China) as reported previously.45 Briefly, cells were digested with
0.25% trypsin and suspended the cells in Mito-Cyto extraction buffer
and grinded 30–40 times on ice. The cell lysate was centrifuged at
800 g for 5 min at 4C to pellet the nucleus and cell debris. The super-
natant was collected and centrifuged at 800 g for 5 min at 4C again,
and the supernatant was collected and centrifuged at 12,000 g for
10 min at 4C to pellet mitochondria.
Measurement of ROS and D4m
Cells were incubated with 10 mM dichlorofluorescein diacetate
(DCF-HA, Sigma, St. Louis, MO) in the dark at 37C for 30 min
then washed three times with PBS. Green fluorescence intensity was
determined by high content analysis (Cellomics Array Scan Infinity;
Thermo Scientific, Waltham, MA) at 488/530 nm. The D4m was
measured using JC-1 (Sigma, St. Louis, MO), a dual-emission mem-
brane potential-sensitive probe that exists as a green fluorescent
monomer at a low D4m and shows red/orange fluorescence in the
aggregate form at a higher D4m. JC-1 (1.3 mg/mL) was added to
cultured cells in plate wells after washing twice with PBS for 30 min
at 37C. The change of fluorescence at 488/530 nm was monitored
by high-content screening, and the ratio of red/green fluorescence in-
tensity was determined. The D4m of primary neurons was measured
by loading the tetramethyl rhodamine methyl ester (TMRM; 10 nM;
Invitrogen, Carlsbad, CA) in the medium.
Measurement of Cell Viability
The viability of SK-N-H cells was measured by the MTT assay, which
involved counting the relative number of live cells based on the con-
version of MTT (Sigma, St. Louis, MO) to formazan crystals. The
cytotoxicity was measured by lactate dehydrogenase (LDH) assay,
which was performed using a cytotoxicity detection kit (Roche, Man-
nheim, Germany). A 100 mL aliquot of culture supernatant was used
to determine LDH release, with 100 mL of preservation solution used
as a blank to correct the optical density reading at 490 nm.
Western Blot
Cell or mitochondria pellet was resuspended in RIPA with protease
inhibitor (PI) for 30 min on ice. After four freeze-thaw cycles, the
samples were centrifuged at 12,000 g for 15 min at 4C. Protein
concentrations were determined using a bicinchoninic acid
protein assay kit (Pierce Biotechnology, Rockford, IL). Proteins
were resolved by 10% SDS-PAGE and transferred to a PVDF mem-
brane, which was blocked and then incubated with anti-a-syn (BD
Biosciences, Franklin Lakes, NJ), anti-b-actin (Beijing Guanxingyu,
China), and anti-VDAC1 (Abcam, Cambridge, UK) for 2 hr
at room temperature. After washing three times with TTBS
(20 mM Tris-HCl, 500 mM NaCl, 0.05% Tween20, pH7.5), mem-
branes were incubated with IRDy800 mouse secondary antibody
(LI-COR, Lincoln, NE) at room temperature for 1 hr. Protein bands
were detected using an Odyssey Infrared Imaging system (LI-COR,
Lincoln, NE) and analyzed with ImageJ software (National Institutes
of Health, Bethesda, MD).
Immunofluorescence and Confocal Microscopy
The coverslips containing probed cells were washed three times with
DMEM, then images were acquired using a Leica TCS-SP5 confocal
microscope (Leica Microsystems, Tokyo, Japan) at room tempera-
ture. Fluorescence Alexa594 and TMRM images were acquired using
590 nm excitation and 617 nm emission, and mitotracker red images
were acquired using 543 nm excitation and 579 nm emission. The
EGFP images were acquired using 488 nm excitation and 516 nm
emission.
Gaussia Luciferase PCA
SK-N-SH cells were cultured in 96-well plates with opti-MEM (Invi-
trogen, Carlsbad, CA) with 5% FBS at 37C. The cells with/without
CADY/aptamer complex pretreatment were co-transfected with con-
structs of a-syn-hGLucN and a-syn-hGLucC. After transfection for
24 hr, cells were washed with PBS and replaced with opti-MEM.
Luciferase activity from protein complementation was measured for
live cells in an automated plate reader at 480 nm following the injec-
tion of the cell permeable substrate, coelenterazine (20 mM; Sigma, St.
Louis, MO), with a signal integration time of 2 s.
Neurite Length Measurement
The Cellomics ArrayScan VTI HCS reader high-content imaging
system (Thermo Fisher Scientific, Waltham, MA) was used for auto-
mated image acquisition and morphometric analyses as previously
described.46 Image analysis was performed using the vHCS Scan
software package with a manually optimized version of the Cellomics
Neural Profiling Bioapplication for neurite outgrowth analysis.
MAP2 protein-positive expression was analyzed in Target Activation
Bioapplication. Output from high content image analysis included
measurement of neurite outgrowth (neurites per neuron, neurite length
per neuron). The single neurite length was determined by dividing the
neurite length of the entire neuron by the number of neurites.
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